In a clinical phase I study of advanced leukemias and myelodysplastic syndrome, a significant antileukemia activity was observed at or below maximum tolerated dose, and SAHA effectively inhibited HDAC activity in peripheral blood and bone marrow blasts [15]. The gene discussed is HDAC9; the disease is leukemia.